On Wednesday, HUTCHMED Announced Savolitinib sNDA Accepted in China For Treatment-Naïve Or Previously Treated Patients With Locally Advanced Or Metastatic MET Exon 14 NSCLC
Author: Charles Gross | March 28, 2024 04:55am
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the supplemental New Drug Application ("sNDA") for savolitinib, in adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with mesenchymal epithelial transition factor ("MET") exon 14 skipping alteration, has been accepted for review by the China National Medical Products Administration (NMPA). If approved, the new label indication for savolitinib will be expanded to include treatment-naïve patients in China.
Posted In: FXI HCM